Mineralys' Losses Mount Amid R&D Spend, Cash Position Strong

TL;DR

**MLYS is burning cash fast with rising R&D, but recent capital raises give them a runway to hit key clinical milestones, making it a speculative buy for risk-tolerant investors.**

AI Summary

Mineralys Therapeutics, Inc. reported a net loss of $43.3 million for the three months ended June 30, 2025, an increase from $41.0 million in the prior-year period. For the six months ended June 30, 2025, the net loss was $85.5 million, up from $72.5 million in the same period of 2024. Research and development expenses slightly decreased to $38.3 million for the three months ended June 30, 2025, from $39.3 million in 2024, but increased to $76.2 million for the six-month period from $70.0 million. General and administrative expenses rose to $8.5 million for the quarter and $15.0 million for the six months, compared to $5.9 million and $10.5 million, respectively, in 2024. The company's cash, cash equivalents, and investments totaled $324.9 million as of June 30, 2025, down from $335.3 million in total current assets at the end of 2024. Mineralys funded operations by raising approximately $717.4 million in gross proceeds since inception, including $188.7 million from a public offering and $9.5 million from an ATM Agreement in the first half of 2025. The accumulated deficit reached $388.0 million as of June 30, 2025, reflecting continued significant operating losses. The company believes its current capital is sufficient to fund operations for at least 12 months.

Why It Matters

Mineralys Therapeutics' continued significant net losses, reaching $85.5 million for the first half of 2025, highlight the substantial capital requirements of clinical-stage biopharmaceutical companies. For investors, this underscores the high-risk, high-reward nature of the sector, where profitability is distant. Employees face job security tied to successful clinical trials and continued funding. Customers, specifically patients with hypertension and related cardiorenal conditions, are awaiting the potential market entry of lorundrostat, which could offer a new treatment option in a competitive landscape dominated by established pharmaceutical players. The broader market watches for innovation in cardiovascular medicine, but also for the financial sustainability of companies like Mineralys.

Risk Assessment

Risk Level: high — Mineralys Therapeutics is a clinical-stage biopharmaceutical company with no revenue from product sales and an accumulated deficit of $388.0 million as of June 30, 2025. The company incurred a net loss of $85.5 million and used $75.7 million in cash from operations for the six months ended June 30, 2025, indicating a high burn rate and reliance on external financing for survival.

Analyst Insight

Investors should closely monitor the progress of lorundrostat's clinical trials, particularly the Phase 2 trial for obstructive sleep apnea, as successful outcomes are critical for future valuation. Given the high cash burn and lack of revenue, new investors should consider this a high-risk, long-term speculative investment, while existing investors should assess their risk tolerance and the company's ability to secure additional funding without significant dilution.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$ 335.7M

total Debt

$ 0M

net Income

$ -85.5M

eps

$ -1.44

gross Margin

N/A

cash Position

$ 324.9M

revenue Growth

N/A

Key Numbers

• $85.5M — Net Loss (for the six months ended June 30, 2025, up from $72.5M in 2024)
• $388.0M — Accumulated Deficit (as of June 30, 2025, reflecting ongoing losses)
• $324.9M — Cash, Cash Equivalents, and Investments (as of June 30, 2025, providing liquidity for operations)
• $75.7M — Net Cash Used in Operating Activities (for the six months ended June 30, 2025, indicating high burn rate)
• $76.2M — Research and Development Expenses (for the six months ended June 30, 2025, up from $70.0M in 2024)
• $188.7M — Proceeds from Public Offering (net of offering costs, in the first half of 2025)
• 65,725,409 — Shares Issued and Outstanding (as of June 30, 2025, up from 49,821,915 at Dec 31, 2024)

Key Players & Entities

• Mineralys Therapeutics, Inc. (company) — clinical-stage biopharmaceutical company
• lorundrostat (product) — clinical-stage product candidate
• Nasdaq Global Select Market (market) — exchange where common stock is traded
• U.S. Securities and Exchange Commission (regulator) — governing body for financial reporting
• Delaware (location) — state of incorporation
• Radnor, Pennsylvania (location) — company headquarters
• Chief Executive Officer (person) — chief operating decision maker
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $43.3 million for Q2 2025 and $85.5 million for the first six months of 2025. The accumulated deficit reached $388.0 million as of June 30, 2025, indicating a significant burn rate and reliance on external funding.
• Dependence on Future Financing [high — financial]: Mineralys Therapeutics has raised substantial capital since inception, including $188.7 million from a public offering and $9.5 million from an ATM Agreement in H1 2025. While management believes current capital is sufficient for at least 12 months, continued losses necessitate ongoing access to capital markets.
• Increasing General and Administrative Expenses [medium — operational]: G&A expenses rose to $8.5 million for Q2 2025 and $15.0 million for the six-month period, compared to $5.9 million and $10.5 million in the prior year, respectively. This increase may impact overall profitability if not managed effectively.
• Research and Development Investment [medium — operational]: R&D expenses for the six months ended June 30, 2025, increased to $76.2 million from $70.0 million in the prior year. While necessary for drug development, these significant ongoing costs contribute to the company's net losses.
• Dilution from Share Issuances [medium — financial]: The number of shares issued and outstanding increased from 49,821,915 at December 31, 2024, to 65,725,409 as of June 30, 2025. This significant increase, driven by public offerings and other issuances, can dilute existing shareholders' ownership.

Industry Context

Mineralys Therapeutics operates in the biotechnology sector, focusing on developing novel therapeutics. This industry is characterized by high R&D costs, long development cycles, significant regulatory hurdles, and a high rate of failure. Success is heavily dependent on clinical trial outcomes and securing substantial funding for ongoing research and development.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Mineralys is subject to stringent regulations from bodies like the FDA. Approval processes are lengthy and costly, and any adverse findings or delays in clinical trials can significantly impact development timelines and market access. Compliance with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) is critical.

What Investors Should Do

1. Monitor R&D spend and clinical trial progress.
2. Assess cash burn rate and future financing needs.
3. Evaluate the trend in General and Administrative (G&A) expenses.
4. Track share count and potential dilution.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported net loss of $43.3 million, accumulated deficit of $388.0 million, and cash, cash equivalents, and investments of $324.9 million.
• 2025-01-01: Start of H1 2025 — Company raised $188.7 million from a public offering and $9.5 million from an ATM Agreement, contributing to its funding.
• 2024-12-31: End of Fiscal Year 2024 — Total current assets were $205.351 million, and shares issued and outstanding were 49,821,915.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Indicates the company's history of operating losses, reaching $388.0 million as of June 30, 2025.)

ATM Agreement

At-the-Market agreement, a type of equity offering where a company sells shares of its stock on a stock exchange over a period of time at prevailing market prices. (Mineralys Therapeutics raised $9.5 million through an ATM Agreement in H1 2025, contributing to its cash position.)

Pre-funded warrants

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price, effectively representing immediate ownership of the underlying share. (Mentioned in the context of a private placement offering, indicating a financing strategy used by the company.)

Weighted-average shares used to compute net loss per share

The average number of outstanding shares during a period, adjusted for the timing of share issuances or repurchases. It's used to calculate earnings or loss per share. (Shows an increase from 49,356,287 in H1 2024 to 59,341,368 in H1 2025, reflecting share dilution.)

Year-Over-Year Comparison

Mineralys Therapeutics reported a widening net loss for the six months ended June 30, 2025, to $85.5 million from $72.5 million in the prior year, driven by increased R&D expenses ($76.2M vs $70.0M) and higher G&A costs ($15.0M vs $10.5M). Total assets grew significantly to $335.7 million from $205.9 million, largely due to an increase in investments and cash from recent financing activities. The accumulated deficit also grew to $388.0 million, reflecting the ongoing investment in development.

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq S

Filing Documents

• mlys-20250630.htm (10-Q) — 708KB
• mlys2025q210qex311.htm (EX-31.1) — 9KB
• mlys2025q210qex312.htm (EX-31.2) — 9KB
• mlys2025q210qex321.htm (EX-32.1) — 5KB
• mlys2025q210qex322.htm (EX-32.2) — 5KB
• 0001933414-25-000090.txt ( ) — 3658KB
• mlys-20250630.xsd (EX-101.SCH) — 28KB
• mlys-20250630_cal.xml (EX-101.CAL) — 32KB
• mlys-20250630_def.xml (EX-101.DEF) — 125KB
• mlys-20250630_lab.xml (EX-101.LAB) — 383KB
• mlys-20250630_pre.xml (EX-101.PRE) — 256KB
• mlys-20250630_htm.xml (XML) — 339KB

- Financial Information

Part I - Financial Information 1

Financial Statements

Item 1. Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 32

- Other Information

Part II - Other Information 34

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 35 i Table of Contents

- Financial Information

Part I - Financial Information

Financial Statements

Item 1. Financial Statements Mineralys Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 101,788 $ 114,091 Investments 223,128 84,096 Prepaid and other current assets 10,353 7,164 Total current assets 335,269 205,351 Property and equipment, net 22 53 Other assets 433 499 Total assets $ 335,724 $ 205,903 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,164 $ 479 Accrued liabilities 19,009 14,167 Total current liabilities 22,173 14,646 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 65,725,409 and 49,821,915 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 6 5 Additional paid-in capital 701,548 493,770 Accumulated deficit ( 388,003 ) ( 302,518 ) Total stockholders' equity 313,551 191,257 Total liabilities and stockholders' equity $ 335,724 $ 205,903 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 38,278 $ 39,273 $ 76,157 $ 70,027 General and administrative 8,468 5,895 15,036 10,503 Total operating expenses 46,746 45,168 91,193 80,530 Loss from operations ( 46,746 ) ( 45,168 ) ( 91,193 ) ( 80,530 ) Interest income, net 3,474 4,152 5,713 8,005 Other income (expense) ( 2 ) 2 ( 5 ) 3 Total other income, net 3,472 4,154 5,708 8,008 Net loss $ ( 43,274 ) $ ( 41,014 ) $ ( 85,485 ) $ ( 72,522 ) Net loss per share attributable to common stockholders, basic and diluted $ ( 0.66 ) $ ( 0.83 ) $ ( 1.44 )

View Full Filing

View this 10-Q filing on SEC EDGAR